Elbasvir/grazoprevir in children aged 3-18 years with chronic HCV genotype 1 or 4 infection: a pharmacokinetic modeling study

Overview

cited authors

Gonzalez-Peralta, Regino P.; Wirth, Stefan; Squires, Robert H.; Mutschler, Frauke; Lang, Thomas; Pawlowska, Malgorzata; Sluzewski, Wojciech; Majda-Stanislawska, Ewa; Fischler, Bjorn; Balistreri, William F.; Jonas, Maureen M.; Blondet, Niviann; Rosenthal, Philip; Alkhouri, Naim; Romero, Rene; Grandhi, Anjana; Castronuovo, Patricia; Caro, Luzelena; Du, Lihong; Rosenbloom, Daniel I. S.; Haber, Barbara A.

Publication Date

March 1, 2023

webpage

Web of Science

published in

HEPATOLOGY COMMUNICATIONS Journal

301 E Princeton St., Orlando, FL 32804 | FH.RAS@AdventHealth.com | 407-200-2901

The information on this website is not a substitute for examination, diagnosis, and medical care provided by a licensed and qualified health professional. Please consult your physician before undertaking any form of medical treatment and/or adopting any exercise program or dietary guidelines. If you think you may have a medical emergency, call your physician or 911 immediately. AdventHealth Research Institute reserves the right to add, remove or edit content on this page at its sole discretion.